GlassScriptPhysician profile
Violeta Mihailescu
NPI 1194832691
$560.48
in general payments reported to CMS, 2019-2025
16 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.36 · 2023: $19.37 · 2024: $217 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $82.82 | 2021-2025 | Arexvy, Shingrix |
| Lilly USA, LLC | $69.89 | 2024-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $61.18 | 2025 | Wegovy, Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $50.53 | 2024-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $37.42 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $36.66 | 2024 | Veozah |
| Pfizer INC. | $36.03 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.11 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.61 | 2024 | Caplyta |
| Hologic Sales and Service, LLC | $21.70 | 2025 | Aptima, Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $21.54 | 2025 | Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.34 | 2025 | Jardiance |
| Exact Sciences Corporation | $17.49 | 2024 | Cologuard Collection Kit |
| Phadia US INC. | $17.03 | 2025 | Immunocap |
| Idorsia Pharmaceuticals US INC | $16.08 | 2024 | Quviviq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14.05 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Violeta Mihailescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.